Ex-Merck Partner Symphogen Expects €67.5m To Burn A Hole In Its R&D Pocket
This article was originally published in Scrip
If all goes to plan, Symphogen – the Danish biotechnology company developing antibody mixture therapies to treat cancer – expects to need more cash within a year, despite raising €67.5m via a convertible debt facility from existing investors this week. The round was led by Novo A/S and the Danish pension fund PKA.
Register for our free email digests: